Kodiak Sciences to Host Investor R&D Day on July 16, 2025
Kodiak Sciences (NASDAQ: KOD), a precommercial retina-focused biotechnology company, will host a virtual investor R&D Day on July 16, 2025, from 4:00 PM to 5:30 PM ET. The event will showcase the company's three late-phase clinical assets - tarcocimab, KSI-501, and KSI-101 - with presentations from senior leadership and industry experts.
The company's ABC Platform® uses molecular engineering to combine protein-based and chemistry-based therapies for treating retinal diseases. All three clinical assets are targeting Phase 3 topline data in 2026. The event will be accessible via webcast, with recording available 24 hours after the presentation.
Kodiak Sciences (NASDAQ: KOD), una società biotecnologica focalizzata sulla retina in fase pre-commerciale, organizzerà una giornata virtuale dedicata agli investitori e alla R&D il 16 luglio 2025, dalle 16:00 alle 17:30 ET. L'evento presenterà i tre asset clinici in fase avanzata dell'azienda - tarcocimab, KSI-501 e KSI-101 - con interventi da parte dei dirigenti senior e di esperti del settore.
La piattaforma ABC® dell'azienda utilizza l'ingegneria molecolare per combinare terapie a base proteica e chimica per il trattamento delle malattie retiniche. Tutti e tre gli asset clinici puntano a dati principali di Fase 3 nel 2026. L'evento sarà accessibile tramite webcast, con la registrazione disponibile 24 ore dopo la presentazione.
Kodiak Sciences (NASDAQ: KOD), una empresa biotecnológica precomercial enfocada en la retina, organizará un Día virtual de I+D para inversores el 16 de julio de 2025, de 4:00 PM a 5:30 PM ET. El evento mostrará los tres activos clínicos en fase avanzada de la compañía - tarcocimab, KSI-501 y KSI-101 - con presentaciones de la alta dirección y expertos de la industria.
La plataforma ABC® de la compañía utiliza ingeniería molecular para combinar terapias basadas en proteínas y en química para tratar enfermedades retinianas. Los tres activos clínicos buscan datos principales de Fase 3 en 2026. El evento será accesible vía webcast, con grabación disponible 24 horas después de la presentación.
Kodiak Sciences (NASDAQ: KOD)는 전임상 망막 중심 생명공학 회사로서, 2025년 7월 16일 오후 4시부터 5시 30분(동부시간)에 가상 투자자 연구개발(R&D) 데이를 개최합니다. 이번 행사에서는 회사의 3가지 후기 임상 자산인 타르코시맙(tarcocimab), KSI-501, KSI-101을 선임 경영진과 업계 전문가들이 발표할 예정입니다.
회사의 ABC 플랫폼®은 분자 공학을 활용해 단백질 기반 및 화학 기반 치료제를 결합하여 망막 질환을 치료합니다. 세 가지 임상 자산 모두 2026년 3상 주요 데이터를 목표로 하고 있습니다. 행사는 웹캐스트를 통해 진행되며, 발표 후 24시간 내에 녹화본이 제공됩니다.
Kodiak Sciences (NASDAQ : KOD), une société biotechnologique précommerciale spécialisée dans la rétine, organisera une journée virtuelle R&D pour les investisseurs le 16 juillet 2025 de 16h00 à 17h30 ET. L'événement mettra en lumière les trois actifs cliniques en phase avancée de l'entreprise - tarcocimab, KSI-501 et KSI-101 - avec des présentations de la direction et d'experts du secteur.
La plateforme ABC® de la société utilise l'ingénierie moléculaire pour combiner des thérapies à base de protéines et de chimie afin de traiter les maladies rétiniennes. Les trois actifs cliniques visent à obtenir des données principales de phase 3 en 2026. L'événement sera accessible en webcast, avec un enregistrement disponible 24 heures après la présentation.
Kodiak Sciences (NASDAQ: KOD), ein biotechnologisches Unternehmen mit Fokus auf die Netzhaut in der vorkommerziellen Phase, veranstaltet am 16. Juli 2025 von 16:00 bis 17:30 Uhr ET einen virtuellen Investor R&D Day. Bei der Veranstaltung werden die drei klinischen Spätphasenprodukte des Unternehmens – tarcocimab, KSI-501 und KSI-101 – mit Präsentationen von Führungskräften und Branchenexperten vorgestellt.
Die ABC Platform® des Unternehmens nutzt molekulares Engineering, um proteinbasierte und chemiebasierte Therapien zur Behandlung von Netzhauterkrankungen zu kombinieren. Alle drei klinischen Produkte streben Topline-Daten der Phase 3 im Jahr 2026 an. Die Veranstaltung ist per Webcast zugänglich, eine Aufzeichnung steht 24 Stunden nach der Präsentation zur Verfügung.
- None.
- None.
The virtual event will feature a comprehensive overview of Kodiak's three late-phase clinical assets (tarcocimab, KSI-501, KSI-101) through presentations from members of Kodiak's senior leadership team complemented by distinguished industry experts.
A live webcast of this event will be available to investors and other interested parties.
Registration for the event is available here: https://edge.media-server.com/mmc/p/crrqmwef, as well as on the "Events and Presentations" section of Kodiak's website at https://ir.kodiak.com.
A recording of the webcast and presentation can be viewed as early as 24 hours after the event.
Kodiak Sciences Inc.
Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform® uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's maturing pipeline includes three late-phase clinical assets, all three targeting Phase 3 topline data in 2026.
For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC®, ABC Platform®, ABCD™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding Kodiak's plans, commitments, aspirations and goals related to Kodiak's drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in Kodiak's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC") as well as discussions of potential risks, uncertainties, and other important factors in Kodiak's subsequent filings with the SEC. All information in this press release is as of the date presented, and Kodiak undertakes no duty to update such information unless required by law.
View original content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-host-investor-rd-day-on-july-16-2025-302502115.html
SOURCE Kodiak Sciences Inc.
FAQ
When is Kodiak Sciences (KOD) hosting its Investor R&D Day in 2025?
What clinical assets will Kodiak Sciences (KOD) discuss at its R&D Day?
How can investors access Kodiak Sciences' R&D Day presentation?
What is Kodiak Sciences' ABC Platform technology?
When will Kodiak Sciences report Phase 3 data for its clinical assets?
